SCHEMBL6611299

SCHEMBL6611299

C=C(C(=O)OC)N(Cc1ccccc1NC(=O)c1cccc(F)c1F)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 4/20 0.42
MMP9 P14780 4/20 0.41
MMP13 P45452 4/20 0.41
MMP1 P03956 3/20 0.41
ADAM17 P78536 1/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 2/20 0.41
BMP1 P13497 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KEAP1 Q14145 2/20 0.40
POLB P06746 1/20 0.39
GRK2 P25098 1/20 0.39
PPARG P37231 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
CXCR3 P49682 1/20 0.39
TAS2R14 Q9NYV8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656436 0.85 LMNA (0.48) KDM4EMAPTKMT2ABMP1KEAP1
SCHEMBL6608937 0.84 MEN1 (0.47) ALDH1A1KDM4EMAPTKMT2APOLB
SCHEMBL6607599 0.84 TAS2R14 (0.44) ALDH1A1KDM4EMMP9MMP1MAPT
SCHEMBL5656058 0.83 POLB (0.48) ALDH1A1KDM4EMMP9MMP13MMP1
SCHEMBL6610598 0.82 FLT1 (0.52) KDM4EMMP9MMP1MAPTCXCR3
SCHEMBL6611811 0.82 KDM4E (0.48) ALDH1A1KDM4EMMP9MMP13MMP1
SCHEMBL6610841 0.82 KEAP1 (0.48) ALDH1A1KDM4EMMP9MMP13MMP1
SCHEMBL6610090 0.81 SNCA (0.47) KDM4EMAPTKMT2AKEAP1POLB
SCHEMBL6609938 0.81 MAPT (0.48) ALDH1A1KDM4EMAPTKMT2AHTT
SCHEMBL6612494 0.81 TAS2R14 (0.46) ALDH1A1KDM4EMAPTKMT2ATAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed